Search details
1.
DFV890: a new oral NLRP3 inhibitor-tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
Infection
; 51(3): 641-654, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-36104613
2.
First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor.
Clin Transl Sci
; 17(5): e13789, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38761014
Results
1 -
2
de 2
1
Next >
>>